[ADAP] Adaptimmune Therapeutics plc


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.05 Change: 0.06 (1.5%)
Ext. hours: Change: 0 (0%)

chart ADAP

Refresh chart

Strongest Trends Summary For ADAP

ADAP is in the medium-term down -71% below S&P in 5 months and down -71% in 6 months. In the long-term down -90% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities60.55 M Cash From Investing Activities-17.16 M Cash From Operating Activities-9.73 M Gross Profit
Net Profit-3.12 M Operating Profit-5.16 M Total Assets88.48 M Total Current Assets86.65 M
Total Current Liabilities29.46 M Total Debt Total Liabilities29.46 M Total Revenue2.44 M
Technical Data
High 52 week14.16 Low 52 week1.94 Last close1.94 Last change-2.02%
RSI14.23 Average true range0.32 Beta1.21 Volume75.45 K
Simple moving average 20 days-34.34% Simple moving average 50 days-42.68% Simple moving average 200 days-56.85%
Performance Data
Performance Week-22.71% Performance Month-43.6% Performance Quart-54.03% Performance Half-61.12%
Performance Year-77.9% Performance Year-to-date-66.26% Volatility daily6.21% Volatility weekly13.89%
Volatility monthly28.47% Volatility yearly98.61% Relative Volume821.28% Average Volume287.49 K
New High New Low


2019-10-09 08:00:00 | Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies

2019-10-01 08:00:00 | Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer

2019-09-30 08:45:00 | Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO

2019-09-16 06:41:29 | Does The Adaptimmune Therapeutics plc NASDAQ:ADAP Share Price Fall With The Market?

2019-09-10 09:01:01 | Adaptimmune ADAP Gets Orphan Drug Status for T-cell Therapy

2019-09-09 08:00:00 | United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4

2019-08-27 08:00:00 | Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients

2019-08-16 11:23:03 | What's in Store for Aytu BioScience's AYTU Q4 Earnings?

2019-08-04 11:09:43 | Edited Transcript of ADAP earnings conference call or presentation 1-Aug-19 12:00pm GMT

2019-08-01 22:24:38 | Adaptimmune Therapeutics ADAP Q2 2019 Earnings Call Transcript

2019-08-01 07:15:00 | New Executive Team Announced at Adaptimmune

2019-08-01 07:15:00 | Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update

2019-07-29 16:05:00 | Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019

2019-07-25 08:00:00 | Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS

2019-07-22 08:00:00 | Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center

2019-07-18 11:00:49 | How Should Investors Feel About Adaptimmune Therapeutics plc's NASDAQ:ADAP CEO Pay?

2019-07-18 08:00:00 | Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE?A4 to Enhance Antitumor Responses

2019-07-09 11:23:03 | Athenex ATNX in Focus: Stock Moves 6.5% Higher

2019-07-09 09:00:01 | Adaptimmune Therapeutics PLC ADAP Upgraded to Strong Buy: Here's Why

2019-06-29 17:37:59 | Is Adaptimmune Therapeutics plc ADAP Going to Burn These Hedge Funds?

2019-06-27 14:54:24 | Hedge Funds Piled Into This Stock Right Before Its 40% Ascend

2019-06-27 08:00:00 | Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer

2019-05-28 10:14:14 | Those Who Purchased Adaptimmune Therapeutics NASDAQ:ADAP Shares A Year Ago Have A 72% Loss To Show For It

2019-05-15 12:28:26 | AdaptImmune partners to advance promising cancer immunotherapies

2019-05-15 08:00:00 | Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products

2019-05-06 07:30:00 | Adaptimmune Reports First Quarter 2019 Financial Results

2019-05-06 07:00:00 | Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors

2019-05-02 07:00:00 | Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting

2019-05-01 08:00:00 | Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019

2019-04-18 16:01:10 | Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting

2019-04-12 15:26:18 | These 3 Falling Knives Are Expected to Outperform

2019-04-02 08:00:00 | Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research AACR Meeting

2019-04-01 08:00:00 | Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research AACR Annual Meeting

2019-03-15 12:06:00 | Does Adaptimmune Therapeutics plc NASDAQ:ADAP Have A Particularly Volatile Share Price?

2019-02-27 18:39:48 | Edited Transcript of ADAP earnings conference call or presentation 27-Feb-19 1:00pm GMT

2019-02-27 07:29:00 | Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update

2019-02-07 11:01:23 | Should You Worry About Adaptimmune Therapeutics plc’s NASDAQ:ADAP CEO Salary Level?

2019-02-07 08:00:00 | Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019

2019-01-28 09:38:02 | Adaptimmune Therapeutics PLC ADAP Upgraded to Buy: Here's What You Should Know

2019-01-08 16:30:09 | Radius Exceeds 2018 Financial Guidance, Provides Updates

2019-01-08 09:54:02 | Alnylam ALNY Reports Preliminary Onpattro Revenues for Q4

2019-01-07 07:30:00 | Dose Escalation in Liver Cancer Study with ADP-A2AFP AFP SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 MAGE-A10 Lung Cancer Study after Favorable Safety Reviews

2019-01-02 10:12:08 | What Percentage Of Adaptimmune Therapeutics plc NASDAQ:ADAP Shares Do Insiders Own?

2018-12-12 08:30:00 | Adaptimmune Announces that Gwen Binder will leave in January 2019

2018-11-28 08:30:00 | Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth

2018-11-16 11:00:38 | uniQure Stock Rose 35.7% Yesterday—Here’s Why

2018-11-14 11:10:39 | What You Must Know About Adaptimmune Therapeutics plc’s NASDAQ:ADAP Financial Strength

2018-11-07 15:30:33 | Edited Transcript of ADAP earnings conference call or presentation 6-Nov-18 1:00pm GMT

2018-11-06 07:30:00 | Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update

2018-10-25 16:30:00 | Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018